Hutchmed (China) Limited — RNS

Regulatory news across HCM, HCM

Date	TIDM	Time	Date	TIDM	TitleTitle (filtered)	Company	Source
24/10/23	HCM	09:30:00	24 Oct 2023	Vesting of awards under the LTIP	HCM	Vesting of awards under the LTIP	Hutchmed (China) Limited	RNS
16/10/23	HCM	09:30:00	16 Oct 2023	Clinical Data to be Presented at ESMO 2023	HCM	Clinical Data to be Presented at ESMO 2023	Hutchmed (China) Limited	RNS
29/09/23	HCM	09:30:02	29 Sept 2023	NDA Submission for Fruquintinib in Japan	HCM	NDA Submission for Fruquintinib in Japan	Hutchmed (China) Limited	RNS
29/09/23	HCM	09:30:02	29 Sept 2023	Total Voting Rights	HCM	Total Voting Rights	Hutchmed (China) Limited	RNS
14/09/23	HCM	09:30:03	14 Sept 2023	Director’s Share Dealing	HCM	Director’s Share Dealing	Hutchmed (China) Limited	RNS
12/09/23	HCM	09:30:02	12 Sept 2023	Phase IIIb Savolitinib Results at WCLC 2023	HCM	Phase IIIb Savolitinib Results at WCLC 2023	Hutchmed (China) Limited	RNS
12/09/23	HCM	07:00:07	12 Sept 2023	Patient Enrollment Completed for Bridging Study	HCM	Patient Enrollment Completed for Bridging Study	Hutchmed (China) Limited	RNS
31/08/23	HCM	09:30:02	31 Aug 2023	Total Voting Rights	HCM	Total Voting Rights	Hutchmed (China) Limited	RNS
29/08/23	HCM	07:00:08	29 Aug 2023	BTD in China for Savolitinib for Gastric Cancer	HCM	BTD in China for Savolitinib for Gastric Cancer	Hutchmed (China) Limited	RNS
21/08/23	HCM	07:00:04	21 Aug 2023	Sovleplenib Phase 3 Study Meets Primary Endpoint	HCM	Sovleplenib Phase 3 Study Meets Primary Endpoint	Hutchmed (China) Limited	RNS
07/08/23	HCM	09:30:01	7 Aug 2023	Exercise of Share Options by a Director	HCM	Exercise of Share Options by a Director	Hutchmed (China) Limited	RNS
31/07/23	HCM	12:00:01	31 Jul 2023	Interim Results and Business Updates	HCM	Interim Results and Business Updates	Hutchmed (China) Limited	RNS
20/07/23	HCM	07:00:09	20 Jul 2023	Breakthrough Therapy Designation for Fruquintinib	HCM	Breakthrough Therapy Designation for Fruquintinib	Hutchmed (China) Limited	RNS
13/07/23	HCM	09:30:01	13 Jul 2023	Changes to Board and Technical Committee	HCM	Changes to Board and Technical Committee	Hutchmed (China) Limited	RNS
10/07/23	HCM	07:00:07	10 Jul 2023	Phase 1 Study of HMPL-415 Initiated	HCM	Phase 1 Study of HMPL-415 Initiated	Hutchmed (China) Limited	RNS
29/06/23	HCM	09:30:00	29 Jun 2023	Blocklisting Six Monthly Return	HCM	Blocklisting Six Monthly Return	Hutchmed (China) Limited	RNS
26/06/23	HCM	09:30:01	26 Jun 2023	HUTCHMED to Announce 2023 Half-Year Results	HCM	HUTCHMED to Announce 2023 Half-Year Results	Hutchmed (China) Limited	RNS
16/06/23	HCM	07:00:05	16 Jun 2023	Phase III FRESCO-2 Results in The Lancet	HCM	Phase III FRESCO-2 Results in The Lancet	Hutchmed (China) Limited	RNS
15/06/23	HCM	15:39:19	15 Jun 2023	MAA of Fruquintinib Validated by the EMA	HCM	MAA of Fruquintinib Validated by the EMA	Hutchmed (China) Limited	RNS
09/06/23	HCM	10:30:03	9 Jun 2023	HUTCHMED Highlights Presentations at EHA and ICML	HCM	HUTCHMED Highlights Presentations at EHA and ICML	Hutchmed (China) Limited	RNS
06/06/23	HCM	10:00:01	6 Jun 2023	LTIP and Share Option Scheme	HCM	LTIP and Share Option Scheme	Hutchmed (China) Limited	RNS
31/05/23	HCM	09:30:00	31 May 2023	Total Voting Rights	HCM	Total Voting Rights	Hutchmed (China) Limited	RNS
26/05/23	HCM	07:00:06	26 May 2023	Fruquintinib NDA Granted Priority Review by FDA	HCM	Fruquintinib NDA Granted Priority Review by FDA	Hutchmed (China) Limited	RNS
26/05/23	HCM	07:00:06	26 May 2023	HUTCHMED Highlights Presentations at ASCO 2023	HCM	HUTCHMED Highlights Presentations at ASCO 2023	Hutchmed (China) Limited	RNS
17/05/23	HCM	09:30:02	17 May 2023	Standard form for notification of major holdings	HCM	Standard form for notification of major holdings	Hutchmed (China) Limited	RNS
12/05/23	HCM	13:15:01	12 May 2023	Annual General Meeting Poll Results	HCM	Annual General Meeting Poll Results	Hutchmed (China) Limited	RNS
12/05/23	HCM	09:30:01	12 May 2023	Board of Directors and Board Committee Membership	HCM	Board of Directors and Board Committee Membership	Hutchmed (China) Limited	RNS
10/05/23	HCM	09:30:01	10 May 2023	Appointment of Independent NED	HCM	Appointment of Independent NED	Hutchmed (China) Limited	RNS
28/04/23	HCM	09:30:01	28 Apr 2023	Total Voting Rights	HCM	Total Voting Rights	Hutchmed (China) Limited	RNS
21/04/23	HCM	09:30:00	21 Apr 2023	Vesting of awards under the LTIP	HCM	Vesting of awards under the LTIP	Hutchmed (China) Limited	RNS
18/04/23	HCM	07:00:07	18 Apr 2023	NDA Acceptance in China for Fruquintinib	HCM	NDA Acceptance in China for Fruquintinib	Hutchmed (China) Limited	RNS
12/04/23	HCM	07:00:07	12 Apr 2023	Presentations at AACR Annual Meeting 2023	HCM	Presentations at AACR Annual Meeting 2023	Hutchmed (China) Limited	RNS
11/04/23	HCM	09:30:02	11 Apr 2023	Intended Retirement of Independent NED	HCM	Intended Retirement of Independent NED	Hutchmed (China) Limited	RNS
11/04/23	HCM	09:30:02	11 Apr 2023	2022 Annual Report and Notice of AGM	HCM	2022 Annual Report and Notice of AGM	Hutchmed (China) Limited	RNS
04/04/23	HCM	10:30:01	4 Apr 2023	HUTCHMED Initiates Registration Phase Enrollments	HCM	HUTCHMED Initiates Registration Phase Enrollments	Hutchmed (China) Limited	RNS
31/03/23	HCM	09:30:01	31 Mar 2023	Total Voting Rights	HCM	Total Voting Rights	Hutchmed (China) Limited	RNS
31/03/23	HCM	07:00:11	31 Mar 2023	Rolling Submission of Fruquintinib US NDA Complete	HCM	Rolling Submission of Fruquintinib US NDA Complete	Hutchmed (China) Limited	RNS
14/03/23	HCM	13:30:01	14 Mar 2023	Closing of Fruquintinib License to Takeda	HCM	Closing of Fruquintinib License to Takeda	Hutchmed (China) Limited	RNS
08/03/23	HCM	08:30:02	8 Mar 2023	Director's Share Dealing	HCM	Director's Share Dealing	Hutchmed (China) Limited	RNS
06/03/23	HCM	08:30:02	6 Mar 2023	Vesting of awards under the LTIP	HCM	Vesting of awards under the LTIP	Hutchmed (China) Limited	RNS
28/02/23	HCM	12:15:02	28 Feb 2023	Publication of Form 20-F	HCM	Publication of Form 20-F	Hutchmed (China) Limited	RNS
28/02/23	HCM	08:30:01	28 Feb 2023	2022 Full Year Results and Business Updates	HCM	2022 Full Year Results and Business Updates	Hutchmed (China) Limited	RNS
27/02/23	HCM	10:00:05	27 Feb 2023	Enrollment Completed in Phase 2 Amdizalisib trial	HCM	Enrollment Completed in Phase 2 Amdizalisib trial	Hutchmed (China) Limited	RNS
31/01/23	HCM	08:30:02	31 Jan 2023	Notice of Results	HCM	Notice of Results	Hutchmed (China) Limited	RNS
23/01/23	HCM	08:00:01	23 Jan 2023	License to Takeda for Fruquintinib outside China	HCM	License to Takeda for Fruquintinib outside China	Hutchmed (China) Limited	RNS
18/01/23	HCM	14:30:02	18 Jan 2023	Inclusion of ORPATHYS in NRDL in China	HCM	Inclusion of ORPATHYS in NRDL in China	Hutchmed (China) Limited	RNS
03/01/23	HCM	08:30:01	3 Jan 2023	Enrollment Completed in Phase 3 Trial	HCM	Enrollment Completed in Phase 3 Trial	Hutchmed (China) Limited	RNS
30/12/22	HCM	08:30:05	30 Dec 2022	Blocklisting Six Monthly Return	HCM	Blocklisting Six Monthly Return	Hutchmed (China) Limited	RNS
19/12/22	HCM	10:00:01	19 Dec 2022	FDA NDA Rolling Submission for Fruquintinib	HCM	FDA NDA Rolling Submission for Fruquintinib	Hutchmed (China) Limited	RNS
15/11/22	HCM	07:00:05	15 Nov 2022	HUTCHMED Announces Strategy Update	HCM	HUTCHMED Announces Strategy Update	Hutchmed (China) Limited	RNS

Showing 151–200 of 297 announcements